Clinical trial
KEYMAKER-U01 Master Study: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents, Pembrolizumab, and Chemotherapy, Alone or in Combination, in Participants With Non-small Cell Lung Cancer (NSCLC)
NCT04165798 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- KEYMAKER-U01 Master Study: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents, Pembrolizumab, and Chemotherapy, Alone or in Combination, in Participants With Non-small Cell Lung Cancer (NSCLC)
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- December 19, 2019
- Completion date
- February 13, 2032
- Enrollment
- 1,065 (estimated)
- Sites
- 47
Conditions
As the registry lists them; a condition with its own page is linked.